Abstract
Motor behaviour in patients with Parkinson’s disease is determined with instrumental tests and rating procedures. Results mirror impairment of an individual patient. Objectives were to determine the associations between two kinds of motion series and rating scores in previously untreated 64 patients and to compare outcomes to controls. The line tracing task asks to follow a given path. It measures the needed interval, the number and duration of contacts to the path. The aiming procedure asks to hit contact plates with a pencil and determines the needed time period and the number of accurate, respectively, missed key strokes. Both tests differed between patients and controls. The line tracing task was more sensitive. The line tracing task asks for a complex motion series performance with more cognitive load. The aiming task prompts for a conduction of preponderant simple, repetitive movement series. Only initially, a complex process of aiming is necessary. Performance of complex motion sequences better differs between patients with Parkinson’s disease and controls than conduction of simple, repetitive movement series.
This is a preview of subscription content, log in via an institution to check access.
modified from https://psydok.psycharchives.de/jspui/bitstream/20.500.11780/1018/1/Mls.pdf, page 7)
modified from https://psydok.psycharchives.de/jspui/bitstream/20.500.11780/1018/1/Mls.pdf, page 7)
Similar content being viewed by others
References
Artusi CA, Imbalzano G, Sturchio A, Pilotto A, Montanaro E, Padovani A, Lopiano L, Maetzler W, Espay AJ (2020) Implementation of mobile health technologies in clinical trials of movement disorders: underutilized potential. Neurotherapeutics 17:1736–1746
Cools R, Frobose M, Aarts E, Hofmans L (2019) Dopamine and the motivation of cognitive control. Handb Clin Neurol 163:123–143
Dai H, Otten B, Mehrkens JH, D’Angelo LT (2013) A portable system for quantitative assessment of parkinsonian rigidity. Conf Proc IEEE Eng Med Biol Soc 2013:6591–6594
Di LG, Ricci M, Al-Wardat M, Schirinzi T, Scalise S, Giannini F, Mercuri NB, Saggio G, Pisani A (2020) Technology-based objective measures detect subclinical axial signs in untreated, de novo Parkinson’s disease. J Parkinsons Dis 10:113–122
Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, Eskofier BM, Merola A, Horak F, Lang AE, Reilmann R, Giuffrida J, Nieuwboer A, Horne M, Little MA, Litvan I, Simuni T, Dorsey ER, Burack MA, Kubota K, Kamondi A, Godinho C, Daneault JF, Mitsi G, Krinke L, Hausdorff JM, Bloem BR, Papapetropoulos S (2016) Technology in Parkinson’s disease: challenges and opportunities. Mov Disord 31:1272–1282
Fahn S, Elton R., Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. N.J Macmillan Health Care Information, pp 153–163
Goetz CG, Stebbins GT, Wolff D, Deleeuw W, Bronte-Stewart H, Elble R, Hallett M, Nutt J, Ramig L, Sanger T, Wu AD, Kraus PH, Blasucci LM, Shamim EA, Sethi KD, Spielman J, Kubota K, Grove AS, Dishman E, Taylor CB (2008) Testing objective measures of motor impairment in early Parkinson’s disease: feasibility study of an at-home testing device. Mov Disord 24:549–554
Lee W, Evans A, Williams DR (2016) Validation of a smartphone application measuring motor function in Parkinson’s disease. J Parkinsons Dis 6:371–382
Lopane G, Mellone S, Corzani M, Chiari L, Cortelli P, Calandra-Buonaura G, Contin M (2018) Supervised versus unsupervised technology-based levodopa monitoring in Parkinson’s disease: an intrasubject comparison. J Neurol 265:1343–1352
Müller T, Harati A (2020) Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson’s disease. J Neural Transm (vienna ) 127:265–272
Müller T, Schäfer S, Kuhn W, Przuntek H (2000) Correlation between tapping and inserting of pegs in Parkinson’s disease. Can J Neurol Sci 27:311–315
Müller T, Kuhn W, Przuntek H (2005) Efficacy of budipine and placebo in untreated patients with Parkinson’s disease. J Neural Transm 112:1015–1023
Nikolaus S, Wittsack HJ, Beu M, Antke C, Hautzel H, Wickrath F, Muller-Lutz A, De Souza Silva MA, Huston JP, Antoch G, Muller HW (2019) Amantadine enhances nigrostriatal and mesolimbic dopamine function in the rat brain in relation to motor and exploratory activity. Pharmacol Biochem Behav 179:156–170
Ricci M, Di LG, Pisani A, Mercuri NB, Giannini F, Saggio G (2020) Assessment of motor impairments in early untreated parkinson’s disease patients: the wearable electronics impact. IEEE J Biomed Health Inform 24:120–130
Acknowledgements
We thank Tanja Steiner, Bettina Marchewitz, Gudrun Edler, Ute Claussnitzer and Christine Stamm for technical assistance. We thank the participating PD patients.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Müller, T., Kuhn, W. Complex motion series performance differs between previously untreated patients with Parkinson’s disease and controls. J Neural Transm 129, 595–600 (2022). https://doi.org/10.1007/s00702-021-02416-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-021-02416-x